Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure

Randomized, Double-blind, Placebo-controlled, Comparative Study of Human Anti-TNF Antibody Adalimumab in Combination with Methotrexate and Methotrexate Alone in Taiwanese Patients with Active Rheumatoid Arthritis

Der-Yuan Chen
Show-Jan Chou
Tsu-Yi Hsieh
Yi-Hsing Chen
Hsin-Hua Chen
Chia-Wei Hsieh
Joung-Liang Lan

April 2009

Adalimumab is a fully humanized monoclonal antibody that blocks tumor necrosis factor (TNF)-α, which...

Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study.

Burmester, Gerd
Matucci-Cerinic, Marco
Mariette, Xavier
Navarro-Blasco, Francisco
Kary, Sonja
Unnebrink, Kristina
Kupper, Hartmut

January 2014

International audienceINTRODUCTION: Patients with active rheumatoid arthritis who had failed at leas...

Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries

Codullo, Veronica
Iannone, Florenzo
Sinigaglia, Luigi
Favalli, Ennio Giulio
Sarzi-Puttini, Piercarlo
Atzeni, Fabiola
Ferraccioli, Gianfranco
Gremese, Elisa
Carletto, Antonio
Giollo, Alessandro
Govoni, Marcello
Bergossi, Francesca
Galeazzi, Mauro
Cantarini, Luca
Salaffi, Fausto
Di Carlo, Marco
Bazzani, Chiara
Pellerito, Raffaele
Sebastiani, Marco
Ramonda, Roberta
Lapadula, Giovanni
Caporali, Roberto

January 2017

Targeted drugs against key pathogenetic molecules such as TNF-alpha have significantly improved outc...

EFFECTIVENESS OF ADALIMUMAB FOR RHEUMATOID ARTHRITIS IN PATIENTS WITH A HISTORY OF ANTI-TNF ANTAGONIST THERAPY IN CLINICAL PRACTICE

U. Oezer
S. Kary

April 2015

Objective. To evaluate the effectiveness and safety of adalimumab in patients with rheumatoid arthri...

Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice

P Geusens
K Unnebrink
Gr Burmester
H Kupper
Patrice Fardellone
S Kary
Frank McKenna
U Oezer
Aa Ruiz
Stefano Bombardieri

May 2007

Objective. To evaluate the effectiveness and safety of adalimumab in patients with rheumatoid arthri...

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.

Putte, L.B.A. van de
Rau, R.
Breedveld, F.C.
Kalden, J.R.
Malaise, M.G.
Riel, P.L.C.M. van
Schattenkirchner, M.
Emery, P.
Burmester, G.R.
Zeidler, H.
Moutsopoulos, H.M.
Beck, K.
Kupper, H.

January 2003

OBJECTIVES: To evaluate efficacy, dose response, safety, and tolerability of adalimumab (D2E7) in di...

Adalimumab effect in a cohort of Libyan patients with rheumatic diseases

Basma, E
Rajab, T
Manal, E

July 2017

Background: Adalimumab is a recombinant human IgG1 monoclonal antibody. It is a tumour necrosis fact...

A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis.

Broeder, A. den
Putte, L.B.A. van de
Rau, R.
Schattenkirchner, M.
Riel, P.L.C.M. van
Sander, O.
Binder, C.
Fenner, H.
Bankmann, Y.
Velagapudi, R.
Kempeni, J.
Kupper, H.

January 2002

OBJECTIVE: To assess the pharmacokinetics, safety profile, and efficacy of the fully human anti-tumo...

Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice

BOMBARDIERI, STEFANO
RUIZ AA
FARDELLONE P
GEUSENS P
MCKENNA F
UNNEBRINK K
OEZER U
KARY S
KUPPER H
BURMESTER GR
RESEARCH IN ACTIVE RHEUMATOID ARTHRITIS REACT STUDY GROUP

January 2007

OBJECTIVE: To evaluate the effectiveness and safety of adalimumab in patients with rheumatoid arthr...

Adalimumab alone and in combination with disease- modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: The Research in Active Rheumatoid Arthritis (ReAct) trial.

BURMESTER GR
MARIETTE X
MONTEAGUDO SAEZ I
MALAISE M
TZIOUFAS AG
BIJLSMA JW
UNNEBRINK K
KARY S
KUPPER H.
MONTECUCCO, CARLOMAURIZIO

January 2007

Objective: To evaluate the safety and effectiveness of adalimumab alone or in combination with stand...

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study

van de Putte, L. B. A.
Rau, R.
Breedveld, F. C.
Kalden, J. R.
Malaise, Michel
van Riel, P L C M
Schattenkirchner, M.
Emery, P.
Burmester, G. R.
Zeidler, H.
Moutsopoulos, H. M.
Beck, K.
Kupper, H.

January 2003

OBJECTIVES: To evaluate efficacy, dose response, safety, and tolerability of adalimumab (D2E7...

The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis.

Feuchtenberger, M.
Kleinert, S.
Scharbatke, E.C.
Gnann, H.
Behrends, F.
Wittig, B.M.
Greger, G.
Tony, H.P.

January 2015

OBJECTIVES: The aim of this study is to use data from a non-interventional study of adalimumab in pa...

Adalimumab in rheumatoid arthritis treatment: a systematic review and meta-analysis of randomized clinical trials

Ávila Machado, Marina Amaral de
Maciel, Alessandra Almeida
Pires de Lemos, Lívia Lovato
Costa, Juliana Oliveira
Kakehasi, Adriana Maria
Andrade, Eli Iola Gurgel
Cherchiglia, Mariangela Leal
Assis Acurcio, Francisco de

October 2013

AbstractSince the discovery of the role of tumor necrosis factor in the physiopathological process o...

A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis

Wiens, Astrid
Correr, Cassyano Januário
Venson, Rafael
Otuki, Michel Fleith
Pontarolo, Roberto

June 2010

Adalimumab (ADA) is a monoclonal antibody. Published studies indicate that its use in patients with ...

Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: Experience of the Italian biologics registries

Codullo, Veronica
Iannone, Florenzo
Sinigaglia, Luigi
Favalli, Ennio Giulio
Sarzi-Puttini, Piercarlo
Atzeni, Fabiola
Ferraccioli, Gianfranco
Gremese, Elisa
Carletto, Antonio
Giollo, Alessandro
Govoni, Marcello
Bergossi, Francesca
Galeazzi, Mauro
Cantarini, Luca
Salaffi, Fausto
Di Carlo, Marco
Bazzani, Chiara
Pellerito, Raffaele
Sebastiani, Marco
Ramonda, Roberta
Lapadula, Giovanni
Caporali, Roberto

January 2017

Objective Targeted drugs against key pathogenetic molecules such as TNF-alpha have significantly imp...

Randomized, Double-blind, Placebo-controlled, Comparative Study of Human Anti-TNF Antibody Adalimumab in Combination with Methotrexate and Methotrexate Alone in Taiwanese Patients with Active Rheumatoid Arthritis

Der-Yuan Chen
Show-Jan Chou
Tsu-Yi Hsieh
Yi-Hsing Chen
Hsin-Hua Chen
Chia-Wei Hsieh
Joung-Liang Lan

April 2009

Adalimumab is a fully humanized monoclonal antibody that blocks tumor necrosis factor (TNF)-α, which...

Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study.

Burmester, Gerd
Matucci-Cerinic, Marco
Mariette, Xavier
Navarro-Blasco, Francisco
Kary, Sonja
Unnebrink, Kristina
Kupper, Hartmut

January 2014

International audienceINTRODUCTION: Patients with active rheumatoid arthritis who had failed at leas...

Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries

Codullo, Veronica
Iannone, Florenzo
Sinigaglia, Luigi
Favalli, Ennio Giulio
Sarzi-Puttini, Piercarlo
Atzeni, Fabiola
Ferraccioli, Gianfranco
Gremese, Elisa
Carletto, Antonio
Giollo, Alessandro
Govoni, Marcello
Bergossi, Francesca
Galeazzi, Mauro
Cantarini, Luca
Salaffi, Fausto
Di Carlo, Marco
Bazzani, Chiara
Pellerito, Raffaele
Sebastiani, Marco
Ramonda, Roberta
Lapadula, Giovanni
Caporali, Roberto

January 2017

Targeted drugs against key pathogenetic molecules such as TNF-alpha have significantly improved outc...

EFFECTIVENESS OF ADALIMUMAB FOR RHEUMATOID ARTHRITIS IN PATIENTS WITH A HISTORY OF ANTI-TNF ANTAGONIST THERAPY IN CLINICAL PRACTICE

U. Oezer
S. Kary

April 2015

Objective. To evaluate the effectiveness and safety of adalimumab in patients with rheumatoid arthri...

Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice

P Geusens
K Unnebrink
Gr Burmester
H Kupper
Patrice Fardellone
S Kary
Frank McKenna
U Oezer
Aa Ruiz
Stefano Bombardieri

May 2007

Objective. To evaluate the effectiveness and safety of adalimumab in patients with rheumatoid arthri...

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.

Putte, L.B.A. van de
Rau, R.
Breedveld, F.C.
Kalden, J.R.
Malaise, M.G.
Riel, P.L.C.M. van
Schattenkirchner, M.
Emery, P.
Burmester, G.R.
Zeidler, H.
Moutsopoulos, H.M.
Beck, K.
Kupper, H.

January 2003

OBJECTIVES: To evaluate efficacy, dose response, safety, and tolerability of adalimumab (D2E7) in di...

Adalimumab effect in a cohort of Libyan patients with rheumatic diseases

Basma, E
Rajab, T
Manal, E

July 2017

Background: Adalimumab is a recombinant human IgG1 monoclonal antibody. It is a tumour necrosis fact...

A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis.

Broeder, A. den
Putte, L.B.A. van de
Rau, R.
Schattenkirchner, M.
Riel, P.L.C.M. van
Sander, O.
Binder, C.
Fenner, H.
Bankmann, Y.
Velagapudi, R.
Kempeni, J.
Kupper, H.

January 2002

OBJECTIVE: To assess the pharmacokinetics, safety profile, and efficacy of the fully human anti-tumo...

Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice

BOMBARDIERI, STEFANO
RUIZ AA
FARDELLONE P
GEUSENS P
MCKENNA F
UNNEBRINK K
OEZER U
KARY S
KUPPER H
BURMESTER GR
RESEARCH IN ACTIVE RHEUMATOID ARTHRITIS REACT STUDY GROUP

January 2007

OBJECTIVE: To evaluate the effectiveness and safety of adalimumab in patients with rheumatoid arthr...

Adalimumab alone and in combination with disease- modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: The Research in Active Rheumatoid Arthritis (ReAct) trial.

BURMESTER GR
MARIETTE X
MONTEAGUDO SAEZ I
MALAISE M
TZIOUFAS AG
BIJLSMA JW
UNNEBRINK K
KARY S
KUPPER H.
MONTECUCCO, CARLOMAURIZIO

January 2007

Objective: To evaluate the safety and effectiveness of adalimumab alone or in combination with stand...

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study

van de Putte, L. B. A.
Rau, R.
Breedveld, F. C.
Kalden, J. R.
Malaise, Michel
van Riel, P L C M
Schattenkirchner, M.
Emery, P.
Burmester, G. R.
Zeidler, H.
Moutsopoulos, H. M.
Beck, K.
Kupper, H.

January 2003

OBJECTIVES: To evaluate efficacy, dose response, safety, and tolerability of adalimumab (D2E7...

The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis.

Feuchtenberger, M.
Kleinert, S.
Scharbatke, E.C.
Gnann, H.
Behrends, F.
Wittig, B.M.
Greger, G.
Tony, H.P.

January 2015

OBJECTIVES: The aim of this study is to use data from a non-interventional study of adalimumab in pa...

Adalimumab in rheumatoid arthritis treatment: a systematic review and meta-analysis of randomized clinical trials

Ávila Machado, Marina Amaral de
Maciel, Alessandra Almeida
Pires de Lemos, Lívia Lovato
Costa, Juliana Oliveira
Kakehasi, Adriana Maria
Andrade, Eli Iola Gurgel
Cherchiglia, Mariangela Leal
Assis Acurcio, Francisco de

October 2013

AbstractSince the discovery of the role of tumor necrosis factor in the physiopathological process o...

A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis

Wiens, Astrid
Correr, Cassyano Januário
Venson, Rafael
Otuki, Michel Fleith
Pontarolo, Roberto

June 2010

Adalimumab (ADA) is a monoclonal antibody. Published studies indicate that its use in patients with ...

Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: Experience of the Italian biologics registries

Codullo, Veronica
Iannone, Florenzo
Sinigaglia, Luigi
Favalli, Ennio Giulio
Sarzi-Puttini, Piercarlo
Atzeni, Fabiola
Ferraccioli, Gianfranco
Gremese, Elisa
Carletto, Antonio
Giollo, Alessandro
Govoni, Marcello
Bergossi, Francesca
Galeazzi, Mauro
Cantarini, Luca
Salaffi, Fausto
Di Carlo, Marco
Bazzani, Chiara
Pellerito, Raffaele
Sebastiani, Marco
Ramonda, Roberta
Lapadula, Giovanni
Caporali, Roberto

January 2017

Objective Targeted drugs against key pathogenetic molecules such as TNF-alpha have significantly imp...

Randomized, Double-blind, Placebo-controlled, Comparative Study of Human Anti-TNF Antibody Adalimumab in Combination with Methotrexate and Methotrexate Alone in Taiwanese Patients with Active Rheumatoid Arthritis

Der-Yuan Chen
Show-Jan Chou
Tsu-Yi Hsieh
Yi-Hsing Chen
Hsin-Hua Chen
Chia-Wei Hsieh
Joung-Liang Lan

April 2009

Adalimumab is a fully humanized monoclonal antibody that blocks tumor necrosis factor (TNF)-α, which...

Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study.

Burmester, Gerd
Matucci-Cerinic, Marco
Mariette, Xavier
Navarro-Blasco, Francisco
Kary, Sonja
Unnebrink, Kristina
Kupper, Hartmut

January 2014

International audienceINTRODUCTION: Patients with active rheumatoid arthritis who had failed at leas...

Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries

Codullo, Veronica
Iannone, Florenzo
Sinigaglia, Luigi
Favalli, Ennio Giulio
Sarzi-Puttini, Piercarlo
Atzeni, Fabiola
Ferraccioli, Gianfranco
Gremese, Elisa
Carletto, Antonio
Giollo, Alessandro
Govoni, Marcello
Bergossi, Francesca
Galeazzi, Mauro
Cantarini, Luca
Salaffi, Fausto
Di Carlo, Marco
Bazzani, Chiara
Pellerito, Raffaele
Sebastiani, Marco
Ramonda, Roberta
Lapadula, Giovanni
Caporali, Roberto

January 2017

Targeted drugs against key pathogenetic molecules such as TNF-alpha have significantly improved outc...

Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure

Abstract

Extracted data

Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure

Abstract

Extracted data

Related items

Related items